Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.

Kislukhin G, Murphy ML, Jafari M, Long AD.

Pharmacogenet Genomics. 2012 Apr;22(4):285-9. doi: 10.1097/FPC.0b013e3283514395.

2.

Using Drosophila melanogaster to identify chemotherapy toxicity genes.

King EG, Kislukhin G, Walters KN, Long AD.

Genetics. 2014 Sep;198(1):31-43. doi: 10.1534/genetics.114.161968.

3.

The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans.

Kislukhin G, King EG, Walters KN, Macdonald SJ, Long AD.

G3 (Bethesda). 2013 Aug 7;3(8):1301-10. doi: 10.1534/g3.113.006619.

4.

Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.

Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.

Jpn J Clin Oncol. 2013 Feb;43(2):193-9. doi: 10.1093/jjco/hys213. Epub 2012 Dec 28.

5.

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group.

Ann Oncol. 2002 Nov;13(11):1749-55.

6.

Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.

Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO).

Onkologie. 2004 Feb;27(1):58-64.

PMID:
15007250
7.

Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.

Bochennek K, Dantonello T, Koscielniak E, Claviez A, Dirksen U, Sauerbrey A, Beilken A, Klingebiel T.

Klin Padiatr. 2013 Nov;225(6):309-14. doi: 10.1055/s-0033-1341489. Epub 2013 Aug 14.

PMID:
23946091
8.

Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.

Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.

Gynecol Oncol. 2001 May;81(2):216-24.

PMID:
11330952
9.

Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.

Tassinari D, Drudi G, Panzini I, Pasini G, Arcangeli V, Fochessati F, Gianni L, Mianulli AM, Oliverio G, Pasquini E, Sartori S, Ravaioli A.

Int J Clin Oncol. 2001 Dec;6(6):279-83.

PMID:
11828946
10.

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.

Goff BA, Holmberg LA, Veljovich D, Kurland BF; Puget Sound Oncology Consortium.

Gynecol Oncol. 2008 Aug;110(2):146-51. doi: 10.1016/j.ygyno.2008.04.037. Epub 2008 Jun 6.

PMID:
18538834
11.

Recurrent ovarian cancer.

Pfisterer J.

Onkologie. 2004 Feb;27(1):7-8. No abstract available.

12.

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.

PMID:
17163259
13.

Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.

Soetekouw PM, Timmer-Bonte JN, van der Drift MA, van Leeuwen F, Wagenaar M, van Die L, Bussink J, Tjan-Heijnen VC.

Int J Clin Oncol. 2013 Dec;18(6):988-96. doi: 10.1007/s10147-012-0476-7. Epub 2012 Sep 27.

PMID:
23011101
14.

Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.

Nemunaitis J, Cunningham CC, Vukelja S, Ruxer RL, Adams N, Rich D, Paulson AS, MacEachern JB.

Cancer Invest. 2004;22(3):360-7.

PMID:
15493356
15.

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.

Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV; Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care; Dana Farber-Harvard Cancer Care.

Gynecol Oncol. 2003 Nov;91(2):293-8.

PMID:
14599858
16.

Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.

Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.

Cancer. 1996 Oct 15;78(8):1701-7.

17.

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R.

J Clin Oncol. 2009 Nov 20;27(33):5634-9. doi: 10.1200/JCO.2008.21.4924. Epub 2009 Sep 28.

18.

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.

Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA.

Gynecol Oncol. 2003 Jun;89(3):486-93.

PMID:
12798716
19.

Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

Miller AA, Al Omari A, Murry DJ, Case D.

Lung Cancer. 2006 Dec;54(3):379-85. Epub 2006 Oct 16.

PMID:
17049403
20.
Items per page

Supplemental Content

Write to the Help Desk